87

## 24h

150

0.4

100

% Viability

50

0.3

0.2

A

HPDE

\*\*\*\*

\*\*\*\* \*\*\*\* \*\*\*\* \*\*\*\*

Abs 450nm

0.1

0 0.0

10-1 100 101

Log [Dose SE (g/mL) ]

F

GI50 = 87.35 g/mL

## 48h

E

GI50 = 88.1 g/mL

200

0.8

150 0.6

B

Dose SE (µg/mL)

\*\*\*\*

\*\*\*\* \*\*\*\* \*\*\*\* \*\*\*\*

Abs 450nm

Abs at 450nm

100 0.4

50 0.2

0 0.0

10-1 100 101

Log [Dose SE (g/mL) ]

G

GI50= 72.05 g/mL

## 72h

150

1.5

100 1.0

C

Dose SE (µg/mL)

\*\*\*\*

\*\*\*\* \*\*\*\* \*\*\*\* \*\*\*\* \*\*\*\*

% Viability

Abs 450nm

50 0.5

0 0.0

10-1 100 101

Log [Dose SE (g/mL) ]

## 96h

150

100

2.5

2.0

H

GI50 =164.00 g/mL

Abs 450nm

1.5

1.0

\*

D

D\* ose SE (µg/mL)

\*\*

\*\*\*\* \*\*\*\* \*\*\*\* \*\*\*\*

% Viability

50

0.5

0 0.0

10-1 100 101

Log [Dose SE (g/mL) ]

Supplementary Figure 3 Viability of HPDE cells treated with SE ranging from 0-1000 µg/mL and Gemcitabine 50nM determined by CCK8 colourimetric assay *HPDE cells treated with SE for A: 24 hours, B: 48 hours, C: 72 hours, D: 96 hours. GI50 values of SE cells E: 88.1 µg/mL for 24 hours F: 87.35 µg/mL for 48 hours G: 72.05 µg/mL for 72 hours and H: 164.00 µg/mL for 96 hours. Significance between treatment groups and the negative control calculated using one-way ANOVA represented over treatment columns by ‘\*’ = p<0.05, ‘\*\*’ = p<0.01, ‘\*\*\*’ = p<0.005, ‘\*\*\*\*’ = p<0.001.*